Literature DB >> 15353484

Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?

David Saadoun1, Felipe Suarez, François Lefrere, Françoise Valensi, Xavier Mariette, Achille Aouba, Caroline Besson, Bruno Varet, Xavier Troussard, Patrice Cacoub, Oliver Hermine.   

Abstract

Hepatitis C virus (HCV) has been associated with the development of B-cell non-Hodgkin lymphomas. We recently reported the regression of splenic lymphoma with villous lymphocytes (SLVL) in patients with HCV after antiviral treatment, demonstrating a direct role of HCV in lymphomagenesis. This study expands our previous results in 18 patients with chronic HCV and SLVL. Mixed cryoglobulinemia (MC) was present in all cases and was symptomatic in 13 (72%). All patients were treated with interferon alone or in association with ribavirin. Hematologic and virologic responses were correlated. Fourteen (78%) patients achieved a sustained complete hematologic response after clearance of HCV RNA. Two patients had a virologic partial response and achieved a complete hematologic response. Two virologic nonresponders achieved partial hematologic response. Regardless of the response, monoclonal immunoglobulin gene rearrangement persisted after treatment. This study underscores the role of HCV in the lymphomagenesis and the benefit of antiviral treatment for patients presenting with HCV-driven lymphoproliferations.

Entities:  

Mesh:

Year:  2004        PMID: 15353484     DOI: 10.1182/blood-2004-05-1711

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Splenic marginal zone lymphoma: hydra with many heads?

Authors:  Luca Arcaini; Marco Paulli
Journal:  Haematologica       Date:  2010-04       Impact factor: 9.941

2.  Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma.

Authors:  Silvia Zibellini; Daniela Capello; Francesco Forconi; Paolo Marcatili; Davide Rossi; Sara Rattotti; Silvia Franceschetti; Elisa Sozzi; Emanuele Cencini; Roberto Marasca; Luca Baldini; Alessandra Tucci; Francesco Bertoni; Francesco Passamonti; Ester Orlandi; Marzia Varettoni; Michele Merli; Silvia Rizzi; Valter Gattei; Anna Tramontano; Marco Paulli; Gianluca Gaidano; Luca Arcaini
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

Review 3.  Hepatitis C virus and lymphoma.

Authors:  D S Viswanatha; A Dogan
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

4.  Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities.

Authors:  Luca Arcaini; Davide Rossi
Journal:  Haematologica       Date:  2012-05       Impact factor: 9.941

5.  Expansion of autoreactive unresponsive CD21-/low B cells in Sjögren's syndrome-associated lymphoproliferation.

Authors:  D Saadoun; B Terrier; J Bannock; T Vazquez; C Massad; I Kang; F Joly; M Rosenzwajg; D Sene; P Benech; L Musset; D Klatzmann; E Meffre; P Cacoub
Journal:  Arthritis Rheum       Date:  2013-04

6.  CD21(-/low) marginal zone B cells highly express Fc receptor-like 5 protein and are killed by anti-Fc receptor-like 5 immunotoxins in hepatitis C virus-associated mixed cryoglobulinemia vasculitis.

Authors:  Benjamin Terrier; Satoshi Nagata; Tomoko Ise; Michelle Rosenzwajg; Ira Pastan; David Klatzmann; David Saadoun; Patrice Cacoub
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

Review 7.  Non-Hodgkin lymphoma and hepatitis C: where we are and what next?

Authors:  Mihály Sulyok; Mihály Makara; Eszter Újhelyi; István Vályi-Nagy
Journal:  Pathol Oncol Res       Date:  2014-10-02       Impact factor: 3.201

Review 8.  Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?

Authors:  Barbara Vannata; Luca Arcaini; Emanuele Zucca
Journal:  Ther Adv Hematol       Date:  2015-12-29

9.  Effect of hepatitis C virus core protein on the molecular profiling of human B lymphocytes.

Authors:  Chuan-ging Wu; Anuradha Budhu; Sheng Chen; Xiaoling Zhou; Nicholas C Popescu; Kristoffer Valerie; Xin Wei Wang
Journal:  Mol Med       Date:  2006 Jan-Mar       Impact factor: 6.354

10.  Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.

Authors:  Monika Joshi; Hassan Sheikh; Kamal Abbi; Sarah Long; Kamal Sharma; Mark Tulchinsky; Elliot Epner
Journal:  Ther Adv Hematol       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.